GSA Capital Partners’s Foghorn Therapeutics FHTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$245K Buy
68,501
+38,995
+132% +$205K 0.01% 1498
2026
Q2
$144K Buy
+29,506
New +$131K 0.01% 1587
2024
Q2
– Sell
-21,855
Closed -$147K – 1751
2024
Q1
$147K Sell
21,855
-19,440
-47% -$108K 0.01% 1450
2023
Q4
$266K Buy
+41,295
New +$178K 0.02% 1178

Other funds holding FHTX

GSA Capital Partners's FHTX Position: Q3 2026 in Review

GSA Capital Partners increased its Foghorn Therapeutics (FHTX) stake by 132% in Q3 2026, buying an estimated $205K and bringing the position to 68,501 shares worth $245K. The position accounts for 0.01% of the portfolio, ranked #1498.

GSA Capital Partners first reported a position in FHTX in Q4 2023 and has held it in 4 quarters since. The position peaked at $266K in Q4 2023. 122 funds tracked by Wall St. Rank hold FHTX as of Q3 2026.

  • GSA Capital Partners held 68,501 shares of Foghorn Therapeutics worth $245K as of Q3 2026.
  • GSA Capital Partners bought 38,995 Foghorn Therapeutics shares in Q3 2026, an estimated $205K.
  • Foghorn Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q3 2026, its #1498 holding.
  • GSA Capital Partners first reported a position in Foghorn Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • GSA Capital Partners's Foghorn Therapeutics position peaked at $266K in Q4 2023.
  • 122 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.